Granules India, a Rs 175-crore Hyderabad company achieved impressive performance during the year ended June 2006 and its net profit has taken a quantum jump of 42.9 per cent to Rs 9.52 crore from Rs 6.66 crore in the previous year. With the smart gain in profitability, its EPS moved up to Rs 7.70 from Rs 5.41.

The company's net sales increased by 32.2 per cent to Rs 176.39 crore from Rs 134.44 crore. Granules India is a backward integrated formulations manufacturer for several pharmaceutical formulation intermediates and active pharmaceutical ingredients. Commenting on the financial performance, C Krishna Prasad, managing director, said " We have prudently invested in people, plants and processes to emerge a completely integrated and dependable pharmaceutical manufacturing outsourcing company in the pharmaceutical formulation space and we intend to be a 'preferred supplier' to large formulation companies overseas."

The company commenced the commercial production from its API plant situated at Bonthapally, Medak Dist., Andhra Pradesh, with a manufacturing capacity of 8000 tpa of paracetamol. Further, the work on the 6-million tablet facility has progressed at advance stage. Both these facilities are been being build with a view to obtain international regulatory approvals. "These backward and forward integrations will help us to offer several generic products in OTC and prescription segments, which strengthen the business of its global formulation customers," he added.